56 Results

People

  1. Moasser
    Moasser
  2. Rosen
    Rosen
  3. Hudis
    Hudis
  4. Norton
    Norton
  5. Dmitrovsky
    Dmitrovsky
  6. Panageas
    Panageas
  7. Seidman
    Seidman
  8. D'Andrea-Carlino
    D'Andrea-Carlino
  9. Dickler
    Dickler
  10. Sepp-Lorenzino
    Sepp-Lorenzino

Groups

  1. Department of Medicine (44)
  2. Solid Tumor Oncology Division (43)
  3. Breast Medicine Service (41)
  4. GSK Faculty (30)
  5. Molecular Pharmacology and Chemistry Program Faculty (28)
  6. Sloan Kettering Institute Faculty (28)
  7. Survivorship Research (17)
  8. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (15)
  9. Epidemiology and Biostatistics (11)
  10. Population Sciences Research Program (11)
  1. "Mark Moasser"
Formats
  1. Meeting Abstract (32)
  2. Journal Article (24)
Groups
  1. Department of Medicine (44)
  2. Solid Tumor Oncology Division (43)
  3. Breast Medicine Service (41)
  4. GSK Faculty (30)
  5. Molecular Pharmacology and Chemistry Program Faculty (28)
  6. Sloan Kettering Institute Faculty (28)

More Groups

People
  1. Mark Moasser (56)
  2. Neal Rosen (28)
  3. Clifford Hudis (15)
  4. Larry Norton (14)
  5. Ethan Dmitrovsky (12)
  6. Andrew Seidman (10)

More People

Years
  1. 2008 (2)
  2. 2005 (3)
  3. 2004 (4)
  4. 2003 (8)
  5. 2002 (6)
  6. 2001 (8)

More Years

Publications
  1. Proceedings of the American Association for Cancer Research Annual Meeting (22)
  2. Clinical Cancer Research (8)
  3. Breast Cancer Research and Treatment (6)
  4. Cancer Research (4)
  5. Oncogene (4)
  6. Cancer Investigation (2)

More Publications

Publishers
  1. American Association for Cancer Research (34)
  2. Springer (6)
  3. Nature Publishing Group (5)
  4. American Society of Clinical Oncology (2)
  5. Elsevier Inc. (2)
  6. Informa Healthcare (2)

More Publishers

Results (56)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer
    Journal Article

    Traina, T. A.; Poggesi, I.; Robson, M.; Asnis, A.; Duncan, B. A.; Heerdt, A.; Dang, C.; Lake, D.; Moasser, M.; Panageas, K.; more...
    Breast Cancer Research and Treatment (2008)

    Fulltext@MSK | Save
  • A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer
    Journal Article

    Dickler, M. N.; Rugo, H. S.; Eberle, C.; Brogi, E.; Caravelli, J.; Panageas, K. S.; Boyd, J.; Yeh, B.; Lake, D. E.; Dang, C.; more...
    Clinical Cancer Research (2008)

    Fulltext@MSK | Save
  • A prospective longitudinal study of the impact of adjuvant chemotherapy for breast cancer (BC) on older patients' functional status and quality of life
    Meeting Abstract

    Hurria, A.; Panageas, K.; Zuckerman, E.; Fornier, M.; D'Andrea, G.; Dang, C.; Moasser, M.; Robson, M.; Seidman, A.; Currie, V.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer
    Journal Article

    Modi, S.; Seidman, A. D.; Dickler, M.; Moasser, M.; D'Andrea, G.; Moynahan, M. E.; Menell, J.; Panageas, K. S.; Tan, L. K.; Norton, L.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane
    Journal Article

    Modi, S.; Currie, V. E.; Seidman, A. D.; Bach, A. M.; Panageas, K. S.; Theodoulou, M.; Moasser, M. M.; D'Andrea, G. M.; Lake, D. E.; Choi, J.; more...
    Clinical Breast Cancer (2005)

    Fulltext@MSK | Save
  • Restoration of PTEN-expression in tumor cells causes them to depend on EGFR for suppression
    Meeting Abstract

    She, Q.; Moasser, M. M.; Ye, Q.; O'reilly, K.; Solit, D.; Rosen, N.
    Cancer Research (2004)

    Fulltext@MSK | Save
  • Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC)
    Meeting Abstract

    Dickler, M.; Rugo, H.; Caravelli, J.; Brogi, E.; Sachs, D.; Panageas, K.; Flores, S.; Moasser, M.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitors
    Journal Article

    Mizenina, O.; Moasser, M. M.
    Cell Cycle (2004)

    Fulltext@MSK | Save
  • Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments
    Journal Article

    Dang, C. T.; Dannenberg, A. J.; Subbaramaiah, K.; Dickler, M. N.; Moasser, M. M.; Seidman, A. D.; D'Andrea, G. M.; Theodoulou, M.; Panageas, K. S.; Norton, L.; more...
    Clinical Cancer Research (2004)

    Fulltext@MSK | Save
  • Pulsatile administration of the EGF receptor inhibitor Iressa (ZD1839) is significantly more effective than continuous dosing for sensitizing tumors to taxol
    Meeting Abstract

    Solit, D. B.; She, Y.; Moasser, M. M.; Hudis, C. A.; Kris, M. G.; Scher, H. I.; Rosen, N.; Sirotnak, F. M.
    Proceedings of the American Association for Cancer Research Annual Meeting (2003)

    Fulltext@MSK | Save